Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke

NCT06987643 is registered in ClinicalTrials.gov with EIP Pharma Inc as lead sponsor.

NCT NCT06987643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06987643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke
Lead sponsor
EIP Pharma Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 20, 2025
Completion date
October 31, 2026
Enrollment
90 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

ischaemic stroke, moderate to severe acute ischaemic stroke